Press Releases Detail:
Avitar CEO Peter P. Phildius to Present Tomorrow At Informed Investors.com Virtual Biotechnology Stocks Forum
December 12, 2001
CANTON, Mass., Dec. 12 /PRNewswire/ -- Avitar, Inc. (Amex: - ) today announced that it will make a presentation at the Informed Investors.com Virtual Biotechnology Stocks Forum tomorrow (Thursday, December 13) at 9:00 a.m. ET.
During the Forum, Peter P. Phildius, Avitar's Chairman and Chief Executive Officer will provide a corporate overview and discuss the company's strategy and vision.
Members of the investment community interested in listening to the presentation can do so by logging onto Avitar's website at avitarinc.com, and following the links to the Forum.
Informed Investors is the leading producer of online and offline industry- specific investment conferences for individual investors and a member of the World Investor Link family of companies serving self-reliant individual investors. Since 1992, World Investor Link (www.worldinvestorlink.com) has opened information channels from public companies to potential investors. This year World Investor Link will make more than 5 million investor introductions to over 4,600 corporate clients world wide through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com), Investor Conference (), and Informed Investors Forums (). World Investor Links' array of products and services enables companies to comply with regulation fair-disclosure requirements by providing investors free access to onsite and webcast investor events and company financial reports. Mutual funds and companies get visibility with investors at the point investors are making decisions through World Investor Link's relationships with over 160 of the leading financial media channels including The Wall Street Journal, Barron's and Yahoo!Finance. World Investor Link, Inc. a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange) began operations in Richmond, Va., in 1993.
Avitar, Inc. (Amex: - ) headquartered in Canton, Massachusetts, is a diagnostics company that develops, manufactures and markets innovative and proprietary medical devices in two major areas: the oral fluid drugs-of-abuse market and the disease & clinical testing market. Oral fluid diagnostics includes both the drugs-of-abuse testing market estimated to be worth $1.5 billion encompassing the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, and HAIRscreen(TM), a laboratory-based hair test for detecting long-term drug abuse. In the $20 billion disease & clinical testing market, Avitar is currently developing products that will address the conditions of Lyme disease, influenza and diabetes, as well as pregnancy. For more information, see Avitar's website at avitarinc.com.
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Ingoldsby Investor Relations